Oculis Holding AG Ordinary Shares OCS 深 沪
已收盘 10-17 16:00:00 美东时间
21.75
+0.200
+0.93%
华盛通- 最 高21.76
- 今 开21.30
- 成交量 9.85万股
- 最 低 21.1944
- 昨 收 21.55
- 总市值 11.10亿
- 52周最高 23.08
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.00
- 委 比 30.83%
- 总股本 5103.37万
- 历史最高 23.08
- 量 比 0.69
- 振 幅 2.62%
- 历史最低 6.26
- 每 手 1
- 风险率 1.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多工业和信息化部部署开展城域“毫秒用算”专项行动
工业和信息化部近日印发通知，部署开展城域“毫秒用算”专项行动。聚焦算力网络发展，构建高速大容量、确定低时延、泛在广覆盖的城域网络，在城域内提供毫秒级算力资源网络...
10-16 20:05
工信部：推动“算力中心毫秒互连”，加强创新技术落地
本文来自：工信部 10月16日，工业和信息化部办公厅组织开展城域“毫秒用算”专项行动，其中提到，聚焦算力网络发展，构建高在城域内提供毫秒级算力资源网络通达能...
10-16 17:03
工信部：开展城域“毫秒用算”专项行动 在城域内提供毫秒级算力资源网络通达能力
以专项行动为牵引，带动产业各方聚焦畅通毫秒用算通道，在全国范围内梯次推进毫秒用算网络建设，到2027年基本形成全域覆盖、高效畅通的城域毫秒用算网络能力体系。
10-16 16:52
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
Oculis Holding AG announced its late-stage pipeline will be highlighted at Eyecelerator and the American Academy of Ophthalmology (AAO) Annual Meeting. Key updates includePrivosegtor advancing into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy, OCS-01 eye drops for diabetic macular edema entering Phase 3 trials with expected results in Q2 2026, and Licaminlimab's upcoming PREDICT-1 trial for d...
10-14 08:00
4 Analysts Have This To Say About TransMedics Group
TransMedics Group (NASDAQ:TMDX) underwent analysis by 4 analysts in the last qu...
10-13 22:01
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Oculis Advances Privosegtor Into FDA-Backed Pivotal Trials, Aiming To Deliver First Neuroprotective Therapy For Vision Loss
Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of
10-06 16:10
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
Oculis Holding AG announces the advancement of Privosegtor into a registrational program for neuro-ophthalmology indications following a positive meeting with the FDA. The PIONEER program includes three pivotal trials targeting AON and NAION. Initial trials will evaluate Privosegtor's efficacy in improving visual function in patients with AON, while PIONEER-3 will focus on NAION. With no approved neuroprotective therapies for these conditions, Oc...
10-06 08:07
